Release Date:  August 16, 1999


National Cancer Institute

The purpose of this Notice is to announce the availability of the "Policy of
the National Cancer Institute for Data and Safety Monitoring of Clinical
Trials."   The policy requires that all clinical trials supported or performed
by NCI be monitored in some form commensurate with the degree of risk involved
in participation and complexity of the clinical trial.  Monitoring exists on a
continuum from monitoring by the principal investigator/project manager to a
data and safety monitoring board (DSMB).  All Phase III randomized clinical
trials supported or performed by NCI require monitoring by a DSMB.  The
organization, responsibilities, and operation of the DSMBs are described in
the policy.

The details of this policy including requirements for data safety and
monitoring can be found at the following location:


General inquiries related to this notice may be directed to:

Richard Mowery, Ph. D.
National Cancer Institute
Executive Plaza North, Suite 712
Bethesda, MD  20892-7424
Telephone:  (301) 496-0510
FAX:  (301) 480-2642

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.